Proactive access strategies for novel cryptosporidiosis therapeutics.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 42008117.
- Also identified by DOI 10.1093/infdis/jiag226.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cryptosporidiosis is a major cause of parasitic diarrhea in lower income countries disproportionately affecting young children, malnourished populations, and people with compromised immunity. While still underemphasized on the global health agenda, the disease is gradually gaining momentum for therapeutic development. However, the real-world impact of any new medicine will hinge on its effective use in regions that currently face significant access barriers. This Perspective asks what it will take to achieve access to new cryptosporidiosis treatments and outlines strategies to bridge scientific progress with real-world delivery.